Prosecution Insights
Last updated: April 19, 2026
Application No. 18/602,538

METHODS AND IMPLANTABLE MEDICAL SYSTEMS THAT IMPLEMENT EXPOSURE MODES OF THERAPY THAT ALLOW FOR CONTINUED OPERATION DURING EXPOSURE TO A MAGNETIC DISTURBANCE

Non-Final OA §112
Filed
Mar 12, 2024
Examiner
VOORHEES, CATHERINE M
Art Unit
3792
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Medtronic, Inc.
OA Round
1 (Non-Final)
83%
Grant Probability
Favorable
1-2
OA Rounds
2y 8m
To Grant
98%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allow Rate
701 granted / 842 resolved
+13.3% vs TC avg
Moderate +14% lift
Without
With
+14.4%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
50 currently pending
Career history
892
Total Applications
across all art units

Statute-Specific Performance

§101
2.6%
-37.4% vs TC avg
§103
37.1%
-2.9% vs TC avg
§102
20.1%
-19.9% vs TC avg
§112
24.6%
-15.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 842 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Priority Claims 30-50 are deemed to have an effective filing date of April 14, 2017 as the provisional application fails to disclose determining a lower pacing rate and a ventricular pacing percentage and comparing the determined values with respective thresholds to select/choose the exposure mode of therapy. Specification The disclosure is objected to because of the following informalities: Paragraph [0007], lines 7-8, of the originally-filed specification (OFS), in pertinent part, reads: “the pacing percentage is not lower than the pacing percentage, then”. The Examiner believes “threshold” is missing from the second recitation of “pacing percentage” as the pacing percentage cannot be lower that itself. In paragraph [0076] of the OFS, line 3, “query operation 808” should be --query operation 806-- to be consistent with the rest of the specification and the drawings. Appropriate correction is required. Claim Objections Claim 43, 44, and 47 are objected to because of the following informalities: The word “heart” is misspelled in line 3, 2, or 2, respectively. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 30 and 32-50 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The term “lower pacing rate” in claims 30 and 50 is a relative term which renders the claim indefinite. The term “lower pacing rate” is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably apprised of the scope of the invention. In addition, it is unclear to what the lower “pacing rate” refers. Is it the pacing rate of the therapy energy as in US 2011/0196450 to McClure et al., paragraph [0057]? Or, the rate of the heart beat (e.g., paragraph [0005] of US 2003/0144706 to Funke)? In addition, the recitation of “the pacing percentage is not lower than the pacing percentage, then choosing” (claim 30, lines 9-10; claim 50, lines 11-12) is indefinite as it appears a word or words are missing. Thus, the scope of claims 30 and 50 is vague and indefinite. Claims 32-49 are rejected because they depend from an indefinite claim. Conclusion The prior art made of record and not relied upon is considered pertinent to applicant's disclosure. US Patent Application Publication No. 2011/0077706 to Ellingson et al. is directed to automatic selection of parameters of an exposure mode of an implantable medical device (IMD). Ellingson discloses that its processor may determine a pacing percentage and when the pacing percentage is less than the threshold pacing percentage, the processor selects a non-pacing mode (e.g., paragraph [0083]). In addition, when the pacing percentage is greater than or equal to the threshold pacing percentage (i.e., not lower than), the processor chooses an operating mode, which could be a permanent pacing mode. Ellingson discloses determining a heart rate and a rate of therapy, but, in as much as the claim is understood, does not appear to choose a non-pacing rate when a lower pacing rate is lower than rate threshold (see paragraphs [0086] and [0113]: when the determined pacing rate is less than the threshold heart rate, the processor may set a pacing mode with a pacing rate of 85 beats per minute) . US Patent Application Publication No. 2003/0144706 to Funke is directed to a method and apparatus for controlling an IMD in response to the presence of a magnetic field which discloses parasystoly occurs when the IMD attempts to stimulate the heart at a rate lower than the patient’s actual spontaneous heart rate (e.g., paragraph [0005]); but does not appear to describe when the heart rate/energy/stimulation rate is less than the rate threshold. US Patent Application Publication No. 2011/0196450 to McClure et al. is directed to an electronic prescription activation device and teaches that an IMD may be programmed with the electronic prescription before the patient has a medical procedure such as an MRI scan (e.g., paragraphs [0056]-[0057]). Any inquiry concerning this communication or earlier communications from the examiner should be directed to CATHERINE M VOORHEES whose telephone number is (571)270-3846. The examiner can normally be reached Monday-Friday 8:30 AM to 4:30 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Unsu Jung can be reached at 571 272-8506. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CATHERINE M VOORHEES/ Primary Examiner, Art Unit 3792
Read full office action

Prosecution Timeline

Mar 12, 2024
Application Filed
Nov 14, 2025
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594034
WEARABLE DEVICE AND METHOD FOR MEASURING BIOMETRIC INFORMATION
2y 5m to grant Granted Apr 07, 2026
Patent 12594416
VENA CAVAL OCCLUSION
2y 5m to grant Granted Apr 07, 2026
Patent 12582825
TRANSLATION BETWEEN CATHODIC AND ANODIC NEUROMODULATION PARAMETER SETTINGS
2y 5m to grant Granted Mar 24, 2026
Patent 12569683
IMPLANTABLE HEAD LOCATED RADIOFREQUENCY COUPLED NEUROSTIMULATION SYSTEM FOR HEAD PAIN
2y 5m to grant Granted Mar 10, 2026
Patent 12558553
METHOD OF PRODUCING AN IMPLANTABLE MEDICAL DEVICE
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
83%
Grant Probability
98%
With Interview (+14.4%)
2y 8m
Median Time to Grant
Low
PTA Risk
Based on 842 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month